COST-EFFECTIVENESS ANALYSIS OF IXEKIZUMAB VERSUS SECUKINUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS AND CONCOMITANT MODERATE-TO-SEVERE PSORIASIS IN SPAIN

被引：1
|
作者：
Schweikert, B. [1 ]
Storck, C. T. [1 ]
Nunez, M. [2 ]
Dilla, T. [3 ]
Hartz, S. [4 ]
Sapin, C. [5 ]
机构：
[1] ICON, Munich, Germany
[2] Eli Lilly & Co, Alcobendas, Spain
[3] Lilly Spain, Madrid, Spain
[4] Eli Lilly & Co, Windlesham, Surrey, England
[5] Eli Lilly & Co, Neuilly Sur Seine, France
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.09.1902
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PMU66
引用
收藏
页码：S319 / S319
页数：1
相关论文
共 50 条
  • [31] Safety Profile of Ixekizumab Treatment in Patients with Moderate-to-Severe Plaque Psoriasis and Psoriatic Arthritis: Integrated Analysis of 18 Clinical Trials
    Genovese, Mark
    Kameda, Hideto
    Rahman, Proton
    Canete, Juan
    Garces, Sandra
    Xu, Wen
    Hufford, Matthew M.
    Combe, Bernard
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [32] Ixekizumab versus FAEs and methotrexate in treatment of nail psoriasis in patients with moderate-to-severe psoriasis
    Augustin, Matthias
    Mrowietz, Ulrich
    Willsmann-Theis, Dagmar
    Gerdes, Sascha
    Fotiou, Konstantinos
    Schuster, Christopher
    Mert, Can
    Holzkaemper, Thorsten
    Behrens, Frank
    Pinter, Andreas
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2024,
  • [33] Reply to: "Comment on 'Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis"'
    Egeberg, Alexander
    Bryld, Lars Erik
    Skov, Lone
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (06) : E379 - E379
  • [34] A Comprehensive Review of Ixekizumab Efficacy in Nail Psoriasis from Clinical Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis
    Bruce W. Kirkham
    Alexander Egeberg
    Frank Behrens
    Andreas Pinter
    Joseph F. Merola
    Thorsten Holzkämper
    Gaia Gallo
    Khai Jing Ng
    Rebecca Bolce
    Christopher Schuster
    Peter Nash
    Luis Puig
    Rheumatology and Therapy, 2023, 10 : 1127 - 1146
  • [35] A Comprehensive Review of Ixekizumab Efficacy in Nail Psoriasis from Clinical Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis
    Kirkham, Bruce W.
    Egeberg, Alexander
    Behrens, Frank
    Pinter, Andreas
    Merola, Joseph F.
    Holzkaemper, Thorsten
    Gallo, Gaia
    Ng, Khai Jing
    Bolce, Rebecca
    Schuster, Christopher
    Nash, Peter
    Puig, Luis
    RHEUMATOLOGY AND THERAPY, 2023, 10 (05) : 1127 - 1146
  • [36] BUDGET IMPACT OF SECUKINUMAB IN THE TREATMENT OF MODERATE-TO-SEVERE PSORIASIS, PSORIATIC ARTHRITIS, AND ANKYLOSING SPONDYLITIS IN MEXICO
    Tierrablanca, L.
    Botello, B. S.
    Gomar, D.
    Ubiarco, V
    VALUE IN HEALTH, 2019, 22 : S252 - S252
  • [37] Efficacy of secukinumab and adalimumab in psoriatic arthritis patients with moderate-to-severe plaque psoriasis: Results from the EXCEED study
    Gottlieb, Alice B.
    Merola, Joseph F.
    Reich, Kristian
    Behrens, Frank
    Nash, Peter
    Bao, Weibin
    Pellet, Pascale
    Pricop, Luminita
    McInnes, Iain B.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB92 - AB92
  • [38] THE IMPORTANCE OF MANAGING ARTHRITIS IN PATIENTS WITH BOTH MODERATE-TO-SEVERE PSORIASIS AND PSORIATIC ARTHRITIS
    Kirkham, B.
    Boggs, R.
    Li, W.
    Nab, H. W.
    Tarallo, M.
    VALUE IN HEALTH, 2013, 16 (03) : A227 - A227
  • [39] COST-EFFECTIVENESS OF SECUKINUMAB IN MODERATE TO SEVERE PSORIASIS COMPARED WITH OTHER BIOLOGICS IN GERMANY
    Graham, C. N.
    McBride, D.
    Miles, L.
    Gilloteau, I
    O'Neill, C. B.
    Neidhardt, K.
    Augustin, M.
    VALUE IN HEALTH, 2017, 20 (05) : A157 - A157
  • [40] A REVIEW OF THE COST-EFFECTIVENESS OF SECUKINUMAB IN THE MANAGEMENT OF PSORIATIC ARTHRITIS
    Alabaku, O.
    Safarudin, R. F.
    Khan, S.
    Khalil, M.
    Kamal, K.
    VALUE IN HEALTH, 2021, 24 : S15 - S15
12345